Invited Review

Gene expression in maturing neurons: regulatory mechanisms and related neurodevelopmental disorders

DING Baojin[*]

Department of Neurobiology, University of Massachusetts Medical School, Worcester, MA 01655, USA

Abstract: During the central nervous system (CNS) development, the interactions between intrinsic genes and extrinsic environment ensure that each neuronal developmental stage (eg. neuronal proliferation, differentiation, migration, axon extension, dendritogenesis and formation of functional synapses) occurs in the proper timing and sequence. The successful coordination requires that numerous groups of genes are exquisitely regulated in a spatiotemporal manner by various regulatory mechanisms, including sequence-specific DNA-binding proteins, histone modifications, DNA methylation, chromatin remodeling, and microRNAs (miRNAs). By targeting chromatin structure, transcription and translation processes, these mechanisms form a regulatory network to accomplish the fine regulation of gene expression in response to environmental stimuli at different developmental stages. Dysregulation of the gene expression during neuronal development has been shown to be implicated in a number of neurodevelopmental disorders, such as autism spectrum disorders (ASD), Rett syndrome (RTT), Fragile-X syndrome (FXS) and other genetic diseases. The further understanding of the regulation of gene expression during neuronal development may provide new approaches for the diagnosis and treatment of these disorders.

Key words: neuronal development; gene expression; regulatory mechanisms; transcription; epigenetics; histone modification; DNA methylation; neurodevelopmental disorders; autism spectrum disorders

神经发育过程中的基因表达调控机制以及相关的神经发育性疾病

丁保金[*]
马萨诸塞大学医学院神经生物系，伍斯特市 01655，美国

摘 要：在中枢神经系统的发育过程中，内在的基因和外在的环境因素相互作用以确保神经元发育的各个阶段(如神经细胞的增殖、分化、迁移，轴突延伸，树突成长，功能性突触的形成等)有序进行。这一过程需要众多的基因表达调控机制对不同基因的表达水平进行精确的时空调节。这些调控机制包括了序列特异性DNA结合蛋白(转录因子等)、组蛋白修饰、DNA甲基化、以及微小RNA (miRNA)等。它们形成了一个调控网络，在神经发育的不同阶段以及不同的环境刺激因素的情况下，从染色质的结构、基因的转录和蛋白质的翻译等不同层次上实现基因表达的精确调控。神经元发育过程中基因表达失调与一些神经发育性疾病相关，例如自闭症谱系障碍，Rett综合征，脆性X综合征以及其他遗传性疾病。深入研究神经元发育过程中基因表达调控机制可望能够给这些神经发育性疾病的诊断和治疗提供新的思路。

关键词：神经发育；基因表达；调控机制；转录；表观遗传学；组蛋白修饰；DNA甲基化；神经发育障碍；自闭症谱系障碍
中图分类号：R338；Q7

1 Introduction

Central nervous system development results from the interactions between intrinsic genes and extrinsic environment. The process of neuronal development consists of successive developmental stages including prolifera-

tion, differentiation, migration, axon extension, dendritogenesis and formation of functional synapses [1, 2]. In this developmental sequence, the interplay between genes and environment ensures that each step must occur in the proper timing and sequence. Their successful regulation requires that numerous groups of genes should be turned on and off in response to extracellular signals in an elegant spatiotemporal manner [3]. Thus, the regulation of gene expression plays a pivotal role in the neuronal developmental program. As the vertebrate brain continues its maturation long after birth, the protracted developmental process renders the vertebrate brain vulnerable to disruptions in this developmental program. Altered spatiotemporal expression of genes required for later neuronal development is likely to affect synaptic connectivity and organization of neuronal networks, leading to functional and behavior disorders [2].

To better understand the spatiotemporal gene expression features in neuronal development, in the first part of this review, cerebellar granular neurons (CGNs) serve as an example to explain the various patterns of gene expression at different developmental stages. CGNs were chosen as a model system in the study of neuronal development because they possess the following unique advantages. First, CGNs are the most abundant neurons in the vertebrate brain, representing more than half of the total neurons [4]. Second, the differentiation process of CGNs has been well defined [3]. Third, CGNs play critical roles in cerebellum (Cb) functions via forming connections between mossy fibers, the major afferent input of the Cb, and Purkinje cells, the sole output of Cb [5, 6]. Moreover, besides motor coordination, increasing evidence indicates that the Cb also plays a significant role in cognitive functions, such as attention, language, emotional behavior, sleep and so on [7, 8]. Actually, this spatiotemporal pattern of gene expression in development is not limited to CGNs, and also can be found in other types of neurons [9–12]. In the second part, the regulatory mechanisms of gene expression in maturing neurons were reviewed, including the regulation by sequence-specific DNA-binding proteins (TFs and activators), epigenetic regulation (histone modifications, DNA methylation, chromatin remodeling), and the regulation by the newly emerged area of microRNAs (miRNAs). Localized mRNA translation is another regulatory mechanism in maturing neurons. It has been reviewed elsewhere [13–15] and will not be fur-

ther discussed here. The third part of this review is about neurodevelopmental disorders (NDs) that are related to the alterations of gene expression during neuronal development, including autism spectrum disorders (ASD), Rett syndrome (RTT), and Fragile-X syndrome (FXS). Advances of human genetics have revealed that some of these disorders are caused by mutations in transcription factors (TFs), transcriptional cofactors, epigenetic control proteins or miRNA [16, 17]. As the space limitation in the text, the detail physiological functions and anatomic structures of different neurons, and the treatment of related disorders are beyond this paper.

2 Spatiotemporal regulation of gene expression in neuronal development

During the neuronal development, the expression patterns of different groups of genes are precisely regulated in a spatiotemporal manner. For example, CGNs, which undergo a well-defined sequence of differentiation in Cb, show a fine spatiotemporal regulation of gene expression during development (Fig. 1*A*). In mouse, granule cell precursors (GCPs) originally arise from a dorsal hindbrain structure called the rhombic lip [18]. Before birth, GCPs leave the rhombic lip and stream cross the outer surface of the Cb to form a region named external germinal layer (EGL). In the first two weeks after birth, cells in EGL undergo extensive proliferation to generate a large pool of GCPs [19]. Increasing numbers of GCPs gradually move inward, then exit the cell cycle and initiate differentiation by extending axons that form synapses with Purkinje cells [20]. With increasing age, the differentiating cells continue to migrate inward through molecular layer (ML) and Purkinje cell layer (PL) until they reach the final destination, internal granule layer (IGL). At 3 weeks of age, the EGL disappears and all GCPs complete their migration and differentiation into mature functional granule cells [19, 21].

Associated with different morphological stages in CGN development, numerous sets of genes are sequentially expressed in different spatiotemporal manners [3]. Many of these genes are characteristic for a given stage of CGN maturation (Fig. 1*A*). For example, *Math1*, which encodes a basic helix-loop-helix (bHLH) transcription factor, is expressed from embryonic day 9.5 in the upper rhombic lip and restricted to the EGL of

Fig. 1. Gene expression is spatially and temporally regulated during neuronal development. *A*: Spatiotemporal sequence of differentiation in mouse cerebellar granular neurons (CGNs). Before birth, granule cell precursors (GCPs) reach the outer surface of the cerebellum to form external germinal layer (EGL). In the first two weeks after birth, GCPs undergo extensive proliferation and gradually move inward, then exit the cell cycle and initiate differentiation by extending axons that form synapses with Purkinje cells. With increasing age, the differentiating cells continue to migrate inward through molecular layer (ML) and Purkinje cell layer (PL) until they reach the internal granule layer (IGL). At 3 weeks after birth, all GCPs complete their migration and differentiation into mature functional granule cells. Different spatiotemporal gene expression patterns are labeled on the right. *Math1* is expressed before birth and restricted to the EGL. *Tag-1* is mainly expressed in postproliferative EGL cells and temporally down-regulated. *Homer 2* is expressed in the migratory and immature IGL cells and slightly expressed in the mature cells. *Gabra6* is temporally up-regulated in mature cells in IGL. *B*: Two major subsets of genes are significantly temporal-regulated during postnatal development in CGNs. One group of genes are highly expressed at early postnatal stage and temporally down-regulated during the development. The other group of genes that are related to mature neuron functions are initially suppressed at early stage and then temporally up-regulated in late maturing process. Figures are modified with permission from references [3, 27].

the Cb by E18. *Math1* mRNA is undetectable in the postmitotic neurons in the following developmental stages [22]. The cell adhesion molecule *Tag-1* is mainly

expressed in postproliferative EGL cells and down-regulated prior to onset of radial migration [23]. Gene *Homer 2* is expressed in the migratory and immature IGL cells and slightly expressed in the mature cells [24]. However, most genes that encode proteins are involved in mature neuron functions, such as *Gabra6*, a subunit of gamma-aminobutyric acid (GABA) A receptor, is expressed in mature cells in IGL and is up-regulated during late development [25, 26].

Genome-wide gene expression analysis indicated that two striking groups of genes were temporally regulated during postnatal development in mouse CGNs (Fig. 1*B*) [27]. One group of genes are highly expressed at early postnatal stage and temporally down-regulated during development. The other group of genes are initially suppressed at early stage and then temporally up-regulated in the late maturing process [27]. Gene Ontology (GO) analysis indicated that the products of genes in the temporal-up group are significantly enriched in synaptic vesicle, dendritic spine, neuronal cell body, axon, synaptic membrane *etc* (Fig. 2*A*). Consistent to the component results, the function and process analysis indicated that the temporal-up genes are mainly involved in neuronal maturation and function, such as neuron differentiation, neuron development, neuron projection morphogenesis, neurotransmitter transport, cell adhesion and cell-cell signaling *etc* (Fig. 2*B*). On the other hand, the products of temporal-down genes are significantly enriched in nucleus, chromosome, condensed chromosome kinetochore, actin filament and cytoskeleton *etc* (Fig. 2*C*), participating processes of mitosis, cell cycle, cell division and migration, neurogenesis *etc* (Fig. 2*D*). (The link to the microarray data sets: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=rtahnkckmemcarq&acc=GSE42018.) Diverse gene expression profiles in maturing neurons indicate that multiple gene regulation mechanisms occur in developmental program.

3 Regulatory mechanisms of gene expression in maturing neurons

Regulatory mechanisms of gene expression have been extensively investigated in neuronal development, including the regulation of TFs and co-activators, chromatin structure and posttranslational modifications. Non-coding RNA has been shown a new regulatory mechanism of gene expression in nervous system.

Fig. 2. Relative enrichment of temporally-regulated genes in cerebellar granular neurons during postnatal development. Temporally-regulated genes were identified by microarray analysis [27] and the data sets have been submitted to GEO data base: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=rtahnkckmemcarq&acc=GSE42018. Gene Ontology (GO) analysis was generated by GENERIC GENE ONTOLOGY TERM FINDER at: http://go.princeton.edu/cgi-bin/GOTermFinder. On each panel, GO ID and term were labeled on left and the *P* values were labeled on right. *A*: The component of temporal-up genes. *B*: The function and process of temporal-up genes. *C*: The component of temporal-down genes. *D*: The function and process of temporal-down genes.

3.1 Transcriptional regulation by sequence-specific DNA-binding proteins

The first and the most rapid transcriptional changes are mediated by nuclear TFs or co-activators that sit prebound and primed at their target gene promoters or enhancers [28]. In response to extrinsic stimuli, posttranslational modifications occur to these TFs and then the changes of protein-protein interactions will rapidly recruit RNA polymerase and facilitate the transcriptional machinery assembling (Fig. 3A). For example, the transcription factor myocyte enhancer factor 2A (MEF2A) is highly expressed in CGNs throughout the period of synaptogenesis [29] and it plays an important role in the synapse development, memory formation, and regulation the growth and pruning of neurons in response to stimulation [30–32]. The sumoylation of MEF2A at lysine-403 forms a transcriptional repressor which promotes dendritic claw differentiation [33]. On the other hand, MEF2A can be dephosphorylated at serine-408 by calcium signaling induced calcineurin (CaN) activity, thereby, promoted a switch from sumoylation to acetylation at lysine-403, resulting in a transactivation form and leading to inhibition of dendritic claw differentiation [33].

A second and slower transcriptional regulation is mediated by TFs that translocate to the nucleus follow-

Fig. 3. Molecular mechanisms of transcriptional regulation by sequence-specific DNA-binding proteins. *A*: Nuclear transcription factors (TFs) prebound and primed at their target gene promoters. In response to extrinsic stimuli, posttranslational modifications (PTMs) occur to these TFs and then recruit RNA polymerase (RNAP) and general TFs (GTFs) to facilitate the transcriptional machinery assembling. *B*: TFs that translocate to the nucleus following stimulation and result in the transcriptional machinery assembling. *C*: Transcriptional regulation is mediated by the removal of transcription suppressors that primed at target gene promoters and prevent the transactivation of target gene (Time 1). During development or in response to extrinsic stimuli, the suppressor is released and makes the target gene promoter accessible to TFs and transactivation occurs (Time 2). *D*: The products of some early response genes are TFs. These TFs could undergo posttranslational modifications or nucleus translocation to target the promoters of late response genes, resulting in the second wave of gene expression in response to extrinsic stimuli.

ing stimulation (Fig. 3*B*). For example, the nuclear factor of activated T-cells (NFAT) family functions in regulation of genes central for many developmental systems [34, 35]. Members of NFATc1-c4 contain both DNA binding domain and Ca^{2+} sensor/translocation domain [36]. NFAT transactivation is dependent on calcium-dependent CaN activity which directly dephosphorylates several residues in Ca^{2+} sensor/translocation domain of NFAT, leading to expose a nuclear localization sequence and nuclear translocation of NFAT [35, 37]. On the contrary, sequential rephosphorylation of Ca^{2+} sensor/translocation domain will cause nuclear export of NFTA and defection of NFAT transactivation [38].

A third transcriptional regulation, important for temporal gene expression, is mediated by the removal of transcription suppressors which prebound at target gene promoters and prevent the transactivation of target genes (Fig. 3*C*). For example, nuclear factor I (NFI) family members, also known as CTF or CAAT box TFs [39], play wide roles in central nervous development [40–42]. Recently, we have identified an NFI-regulated temporal switch program linked to dendrite and synapse formation in developing mouse CGNs [27]. One central feature of this program was temporally-regulated NFI occupancy of late-expressed gene promoters. Interestingly, this switch program and NFI occupancy were regulated by CaN/NFAT signaling pathway. In immature mouse Cb, NFATc4 functions as a transcription suppressor by occupying the target gene promoters and preventing NFI binding. With the development, the binding of NFATc4 is temporally down-regulated and this removal of NFATc4 from target gene promoter makes NFI binding sites accessible and results in the up-regulation of late-expressed genes [27]. Importantly, NFATc4 suppression effect can be regulated by membrane potential change via calcium-dependent CaN activity, suggesting NFI-regulated transcriptional program serves as a critical link between membrane potential changes and synapse formation via the CaN/NFATc4 pathway. Similarly, another suppressor of NFI-regulated temporal switch program is RE1 silencing transcription factor (REST), which occupies the *Gabra6* proximal promoter in CGPs at early postmitotic stage, and its departure mirrors the initial onset of NFI binding to target genes in differentiating CGNs [43].

Finally, the expression of late response genes can be regulated by early response genes that encode TFs (Fig. 3*D*). Posttranslational modifications or nucleus translo-

cation could be required for the recruitment of these TFs to target gene promoters. For example, ets variant gene 1 (Etv1/Er81) transcription factor of the ETS family plays a key role in orchestrating the neuronal activity-dependent gene regulation for terminal maturation of granule cells [44]. The phosphorylation of ETV1 via the brain-derived neurotrophic factor (BDNF)-mediated ERK1/2 cascade up-regulates the battery of maturation genes, including those of the NMDA receptor subunit GRIN2C (glutamate receptor, ionotropic, NMDA2C) and TIAM1 (T-cell lymphoma invasion and metastasis 1) proteins [45].

3.2 Transcriptional regulation by epigenetics

In addition to the regulation of sequence-specific DNA-binding factors, research on neuronal transcriptional regulation in the past decade has been shifted to the investigation of mechanisms that regulate chromatin, including chromatin modifications, DNA methylation and chromatin remodeling [46, 47]. The regulation of mRNA abundance by miRNAs has also been extensively investigated in neuronal development [48]. As these regulatory mechanisms that impact gene expression without changes of the DNA sequence, they are collectively named epigenetics [49, 50].

3.2.1 Histone modifications

The physiological form of our genome is chromatin, which consists of genomic DNA and proteins. Nucleosome, the basic repeating unit of chromatin, is composed of approximately 147 base pair of superhelical DNA wrapped around a histone octamer consisting of two copies of each core histone H2A, H2B, H3 and H4 [51]. Amino (N-) and carboxy (C-) termini of histone proteins (histone tails) are subject to a different pattern of covalent modifications, including acetylation, methylation, phosphorylation, ADP-ribosylation, ubiquitination, *etc*. These different post-transcriptional modifications of individual histone protein occur at specific amino acid residues, such as acetylation and methylation at lysine (K) or arginine (R) residues and phosphorylation at serine (S) or threonine (T) residues, by the actions of certain enzymes (Fig. 4) [52, 53]. Histone modifications represent a fine molecular code that modulates many cellular processes including neuronal development, plasticity and multiple forms of behavioral memory.

Acetylation is one of histone modifications that have been extensively investigated. Acetylation at several lysine residues throughout the N-terminal tails of core

Fig. 4. Regulation of gene expression by epigenetics in neuronal development. Transcription activity can be regulated by histone modifications, such as acetylation (Ac), ubiquitination (Ub), phosphorylation (Ph), and methylation (Me), and each modification is catalyzed by one or more different enzymes. Nucleosome sliding driven by ATPase regulates the transcription activity by uncovering or masking the transcription factor binding sites. DNA methylation of CpG islands may result in stable silencing of gene expression via impairing transcription factor binding and/or recruiting repressive methyl-binding proteins. The target genes either encode neuronal proteins that function during neuronal development, or express transcription regulatory factors, which in turn regulate target genes expression at transcriptional level. Regulation at transcriptional level also regulates non-coding RNAs, such as miRNAs. By repressing translation or targeting mRNA degradation, miRNAs give rise to the fine-tune gene expression profiles. In the process of neuronal development, transcription factors, coactivators, suppressors, histone modifications, DNA methylations, and tons of miRNAs form a regulatory network on gene expression.

histone proteins is generally associated with gene activation and is regarded as an epigenetic mark associated with dynamic chromatin [47]. Histone acetyltransferases (HATs) catalyze the addition of acetyl groups to histone lysine residues and histone deacetylases (HDACs) function to remove these modifications [54–56]. By neutralizing the positive charge of histone proteins, acetylation can effectively decrease the electrostatic affinity between histone tails and negatively charged DNA and loosen the chromatin structure. Finally, various effector proteins, transcriptional coactivators and members of the general transcriptional machinery are recruited and transcription is initiated [57–59].

Another important histone modification is methylation, which can exist in multiple valence states [e.g. mono- (me1), di- (me2), and tri-methylated (me3) forms] and exhibit slow turnover kinetics under normal cellular conditions [47]. The enzymes responsible for the addition and removal of methyl groups are histone methyltransferases (HMTs) and histone demethylases (HDMs), respectively [60, 61]. Histone methylation was once thought as a stable chromatin 'mark' that might act to control chromatin structure and the potentially related patterns of gene expression. However, as numerous sites and valence state-specific HDMs have been discovered, it is further complicated to categorize the methylation states as active or repressive for the gene expression [61]. For example, methylation of lysine 4 or 36 on histone H3 is related to transcriptional initiation and elongation, respectively, whereas methylation of lysine 9 or 27 on H3 is more strongly associated with transcriptional repression and silencing [47]. Moreover, methylation of lysine and arginine residues, some of which overlap with sites of histone acetylation, can be associated with either gene activation or repression depending on the residues being modified [62].

3.2.2 DNA methylation

Mammalia genomic DNA is also subject to methylation throughout the genome by the catalyzation of DNA methyltransferases (DNMTs) that transfer a methyl group from S-adenyl methionine (SAM) to the fifth carbon of a cytosine residue to form 5mC [63]. Three members of DNMTs have been identified, DNMT1, DNMT3a and DNMT3b. DNMT3a and DNMT3b can establish a new methylation pattern to unmodified DNA, while DNMT1 functions in DNA replication to copy the DNA methylation pattern from template DNA strand to the newly synthesized strand [64]. Most DNA methylation occurs on cytosines that precede a guanine nucleotide or CpG islands. The majority of gene promoters, approximately 70%, reside within CpG island [65]. Compared to other stretches DNA, CpG islands contain less nucleosomes and enhance the accessibility of DNA and promoter transcription factor binding [64, 66]. However, the methylation of CpG islands results in stable silencing of gene expression via impairing transcription factor binding and/or recruiting repressive methyl-binding proteins, such as MeCP2, which is mutated in the childhood neurological disorder RTT (see part 4.2 below) [67, 68].

DNMT1 are expressed throughout neuronal development and plays a critical role in the regulation of gene expression in neuronal maturation [69]. For example, glial fibrillary acidic protein (GFAP), which is the main intermediate filament protein in mature astrocytes and also an important component of the cytoskeleton in astrocytes during development [70]. The DNA methylation of the *Gfap* promoter represses its expression in early neurogenesis at E11.5, coinciding with the high expression of DNMT1 [71]. At E14.5, the *Gfap* promoter underdoses DNA demethylation to coincide with the differentiation of the astrocytic lineage [72]. Between E8.5 and E13.5, a window period of neurogenesis, conditional knock out of DNMT1 causes hypomethylation of differentiating neurons and demethylation of the *Gfap* promoter in neuronal precursor cells, resulting in accelerating astrogliogenesis [73]. Hypomethylated neurons show multiple maturation defects including dendritic arborization and impaired neuronal excitability [74]. These studies demonstrated that precise regulation of DNA methylation is critical for differentiation and maturation of the central nervous system.

3.2.3 Chromatin remodeling

Another epigenetic control of gene expression is chromatin remodeling by ATP-dependent chromatin remodeling complexes, which use energy derived from ATP-hydrolysis to induce nucleosome sliding, resulting in uncovering or masking the transcription factor binding sites (Fig. 4) [75]. BRG and BRM, two of mammalian SWI/SNF2-like ATPases, are alternative subunits of chromatin remodeling complexes BAF (Brg/Brm associated factor) [76]. BRG and the npBAF subunits (BAF45a and BAF53a) have been shown to be required for neuronal stem cell/progenitor self-renewal and proliferation [77]. In addition, regulated expression of BRG/BRM has been implicated in orchestrating the developmental changes in gene expression program that underlie neurogenesis and dendrite outgrowth [78, 79]. Furthermore, BRG1 forms a complex with CREST (Ca^{2+}-responsive transcriptional coactivator), which had previously been implicated in activity-dependent dendritic growth [80], plays a critical role in regulating promoter activation by orchestrating a calcium-dependent release of a repressor complex, and a recruitment of an activator complex [81].

3.2.4 Regulation of gene expression by miRNAs

miRNAs, the largest class of non-coding RNAs, are ~22 nucleotides (nts) molecules that act as post-transcriptional regulators of gene expression by repressing translation or targeting mRNA degradation [82]. The miRNAs are initially transcribed in nucleus by RNA polymerase II from intergenic regions, introns or exons of non-coding RNA genes, or within introns of protein-coding genes [83]. This primary (pri-) miRNAs can be recognized by nuclear protein Drosha, which cleaves the pri-miRNA from several kilobase (kb) into 70–80 nts with its RNase III activity under the direction of its co-factor DiGeorge syndrome critical region 8 (DGCR8) protein [84]. The processed precursor (pre)-miRNAs are then exported to cytoplasm, where Dicer further converts pre-miRNAs into the mature 22 nts RNA duplex [85]. The duplex is then unwound and one strand is preferentially loaded into the RNA induced silencing complex (RISC). By imprecise base pairing with sequences in the 3' UTRs (three prime untranslated regions) of target mRNA, miRNAs modulate gene expression through transcript destabilization and translational attenuation [82, 84]. Many miRNAs do not act as on-off switches, but rather fine-tune gene expression profiles [86, 87]. The combined actions of miRNA and TFs are able to elegantly regulate gene expression on a global level in a manner that cannot be achieved by

TFs alone [82].

The accumulating evidence suggests that miRNAs are essential regulators of gene expression in neuronal development. In mouse, the depletion of miRNAs by inactivation of Dicer results in severe reduction of dendritic branch elaboration [88]. Numerous miRNAs have been shown to be presented in central nervous system, including miR-124 [89], miR-9 [90], miR-132 [91], miR-134 [92], miR-137 [93], miR-138 [94], miR-125b [95], miR-128 [96], miR-375 [97]. These neuronal miRNAs have been shown to play important roles at various stages in neuronal development and maturation, including neurogenesis, neurite outgrowth, dendritogenesis, and spine formation [98].

In the mouse brain, miR-124 is the most abundant miRNAs and it accounts for 25%–48% of all brain-expressing miRNAs [99]. In differentiating mouse P19 cells and mouse primary cortical neuron, overexpression of miR-124 promotes neurite outgrowth, while blocking miR-124 function delays neurite outgrowth [100]. By targeting Rho GTPase family members, cell division cycle 42 (Cdc42) and deactivating ras-related C3 botulinum toxin substrate 1 (Rac1), miR-124 diminishes F-actin density and stimulates tubulin acetylation and possibly regulates the cytoskeletal reorganization to promote neurite outgrowth [98, 100]. miR-124 is also an important regulator of the temporal progression of adult neurogenesis in mice subventricular zone (SVZ). By repression of SRY-box containing gene 9 (Sox9), miR-124 inhibits precursor amplification and stimulates differentiation [89]. Thus, miR-124 appears to play a major role in neuronal differentiation via down-regulating genes essential for precursor proliferation, whereas stimulating neuron-specific genes and cytoskeletal rearrangements [98].

The second example of a miRNA involved in neuronal development is miR-9, which is also highly expressed in the nervous system and highly conserved among species [99]. Overexpression of miR-9 in the developing brain has been shown to alter migration and differentiation of neuronal precursors, inducing premature differentiation [90]. By inhibiting tailless gene (TLX), a gene involved in the division of neuronal stem cells, miR-9 attenuated neuronal stem cell proliferation and enhanced differentiation. On the other hand, TLX inhibits miR-9-1, one isoform of miR-9, through binding to a 3' genomic sequence to form a feedback loop regulation in neuronal differentiation [90].

In addition, by down-regulating of the forkhead box protein G1 (Foxg1), miR-9 promotes generation of Cajal-Retziun cells in the medial pallium of the developing telencephalon [101]. Besides Foxg1, several other TFs, such as Elav2, Gsh2, Nr2e1, and Pax6, have been shown to be down-regulated by miR-9 in the transcriptional regulation through various mechanisms [102].

Another two miRNAs, miR-132 and miR-134, that have been extensively investigated for their roles in neurite extension and synapse formation. The expression of miR-132 in rat hippocampus is temporally regulated in the early postnatal stage. Its level is low in the first postnatal week but accelerates between P7 and P21, coinciding in a period of active synaptogenesis [98]. On the contrary, the expression of P250GAP, an NMDA receptor-associated Rho GTPase-activating protein (GAP), which regulates spine morphogenesis, is high in early stage and decreases during maturation [103]. Interestingly, expression of miR-132 in neuronal cells is regulated by the cAMP response element-binding (CREB) protein, a key regulator in neuronal development, plasticity, and maturation. In response to extrinsic stimuli, induction of miR-132 by CREB promotes neurite outgrowth by targeting P250GAP [104]. Similarly, miR-134 is also regulated by activity at transcriptional level. The expression level of miR-134 in the rat hippocampus increases during development and reaches the peak at P13, when synaptic maturation occurs. By targeting Limk1, which regulates spine outgrowth by controlling cytoskeletal reorganization, miR-134 represses spine growth. However, this suppression can be alleviated by BDNF-induced synthesis of Limk1 [48].

In the process of neuronal development, these regulatory mechanisms on gene expression by epigenetics usually work together, or even combine the regulation of sequence-specific DNA-binding proteins (Fig. 4). For example, histone modification and DNA methylation affect the transcription of target neuronal genes or transcriptional regulatory proteins, such as TFs, coactivators, or suppressors. Subsequently, these factors could target other gene promoter regions, forming a regulatory network on transcription (Fig. 4). At posttranscriptional level, numerous groups of miRNAs regulate the abundance of mRNAs, the products of which can be either transcriptional regulatory factors or neuronal proteins that govern the neuronal development. Overall, the regulation of gene expression in neuronal

development is a complex network, which consists of TFs, coactivators, suppressors, histone modifications, DNA methylations, and tons of miRNAs. By targeting chromatin structure, transcription and translation processes, this network accomplishes the exquisite regulation of the neuronal gene expression in response to environmental stimuli at different developmental stages (Fig. 4).

4 NDs

Alterations of gene expression during neuronal development have been shown to be implicated in NDs, such as mental retardation, ASD, RTT, FXS, Angelman syndrome, Down syndrome, and other rare genetic diseases. These disorders can be caused by mutations in TFs, transcriptional cofactors or epigenetically control proteins. Here I took ASD, RTT, and FXS as examples to show the correlation between dysregulation of gene expression in maturing neurons and NDs.

4.1 ASD

ASD is classified as a pervasive developmental disorder (PPD) and characterized by some common clinical features, such as impaired social interactions, communication defects, and repetitive behaviors or a narrow range of interests [105]. In western countries, the prevalence of ASD has increased in recent surveys and current estimates of prevalence is around 20/10 000 [106], and the prevalence in children is around 1/100 to 1/150 [107]. In ASD prevalence, boys are typically affected at least four times more commonly than girls [105]. In 2014, the Centers for Disease Control and Prevention (CDC) released new data on the prevalence of autism in the United States. This surveillance study identified 1 in 68 children as having ASD, and 1 in 42 boys and 1 in 189 girls. In mainland China, as no national-wide systematic epidemiological studies have ever been reported, the number of people who were diagnosed with ASD remains unknown. Based on some local sample surveys in major cities, the estimated prevalence of ASD in children was about 11/10 000 to 16/10 000 [108, 109]. However, some researchers thought that this occurrence ratio of ASD in children in China was possibly underestimated because of differences in diagnostic criteria, finical constraints and technical limitations in rural areas [110, 111]. Thus, it is urgent to initiate a national-wide systematic epidemiological study on the prevalence of ASD in mainland China.

ASDs can be a major source of stress on the long-term health, and social and financial well-being of affected individuals, their families and society as a whole. Although the etiology and pathogenesis of ASD are not very clear yet, ASD is regarded as a highly genetic disorder [112]. It has been clearly demonstrated that ASD can be caused by many different genetic changes. More than 200 autism susceptibility genes, hundreds of copy number variations (CNVs), more than 100 chromosome fragile sites, and thousands of noncoding RNA molecules (snoRNA, miRNA, and piRNA) have been found to have a relationship to autism [113], indicating the etiology of ASD is complex and heterogeneous [114]. In addition, ASD has been noted as a comorbid feature of more than 100 genetic and genomic disorders, including RTT, Angelman syndrome, FXS, Down syndrome and other rare genetic diseases [115, 116].

Genetic studies demonstrated that up to 7%–10% of children with ASD have a variety of *de novo* chromosomal deletions and duplications [105, 117]. For example, X chromosome deletions implicated the *NLGN3* and *NLGN4* genes, which encode neuroligins 3 and 4 [118]. Neuroligins are synaptic adhesion molecules and regulate either the number or the function of synapses [119]. A 2-base-pair deletion in *NLGN4* gene has been identified in a large family with many affected male patients showing mental retardation and/or autism [120]. Another strong genetic association for ASD is *SHANK3* (SH3 and multiple ankyrin repeat domains 3), which encodes a scaffolding protein serving as a binding partner of neuroligins. A mutation of a single copy of *SHANK3* on chromosome 22q13 can result in language and/or social communication disorders [121]. A genome-wide analysis of rare copy-number variation (CNV) in ASD families indicated that there could be 130–234 ASD-related CNV regions in the human genome, including rare *de novo* events at chromosomes 7q11.23, 15q11.2-13.1, 16p11.2, and Neurexin 1 [122]. By using whole-exome (coding regions of the genome) sequencing of substantial individuals, three recent studies identified roles of *de novo* exonic mutations in the pathogenesis in ASD, including *SCN2A* (sodium channel, voltage-gated, type II, alpha subunit) [123], *KATNAL2* (katanin p60 subunit A-like 2), *CHD8* (cadherin 8) [124], *NTNG1* (netrin-G1), *GRIN2B* (glutamate receptor, ionotropic, *N*-methyl *D*-aspartate 2B), *LAMC3* (laminin subunit gamma 3), and *SCN1A* (sodium channel, voltage-gated, type I, al-

pha subunit) [125]. Alterations of trimethylated H3K4 (H3K4me3), a histone mark associated with transcriptional regulation, have been identified in another study [126]. Compared to controls, excess spreading of H3K4me3 from the transcription start sites into downstream gene bodies and upstream promoters was observed specifically in neuronal chromatin from autism cases. Variable subsets of autism cases exhibit altered H3K4me3 peaks at numerous genes regulating neuronal connectivity, social behaviors, and cognition, often in conjunction with altered expression of the corresponding transcripts. These data indicate that loss or excess of H3K4me3 at hundreds of loci leading to dysregulation of gene expression implicated in ASD [126].

Studies of mutations in *NLGN3/NLGN4* and *SHANK3* genes provided the evidence that genes encoding proteins of the neuronal synapse are involved in ASD. In addition, synaptic activity-related signals which regulate protein synthesis within the synaptic spine have been shown to be involved in ASD [127]. By mapping homozygosity in families with shared ancestry, three rare inherited autosomal recessive risk alleles for ASD have been identified, such as *PCDH10* (protocadherin 10), *DIA1* (deleted in autism1) and *NHE9* (Na^+/H^+ exchanger 9) [128]. Interestingly, *PCDH10* and *DIA1* are targets of transcription factor MEF2 (myocyte enhancer factor 2), which plays important roles in activity-dependent transcription in response to membrane depolarization [30, 129]. Gene *NHE9* may be a target of transcriptional regulation by activity-inducible transcription factor Npas4 (neuronal PAS domain protein 4) [130]. These data suggest that defective regulation of gene expression after neuronal activity may be a pathophysiological mechanism that is common to genetically heterogeneous causes of autism [128].

As mentioned above, ASD is a common comorbid feature of other genetic disorders, including some monogenetic disorders. The studies of these monogenetic disorders provided important clues about the mechanisms underlying ASD and also contributed to the understanding of the correlation between gene expression and developmental disorders. Currently, at least two different clusters of genes have been extensively studied for monogenic forms of ASD: 1) genes encoding proteins involved in regulating protein synthesis, or 2) genes encoding structural synaptic proteins [131, 132]. In the following part, two monogenetic NDs will be discussed.

4.2 RTT

RTT is a developmental disorder that predominantly affects females with prevalence around 1 in 10 000. Classic RTT is characterized by apparently normal early development for the first 6 to 18 months of age followed by developmental regression and loss of acquired skills, loss of speech, emergence of autistic features, loss of purposeful hand movements, microcephaly, seizure, ataxia, respiratory abnormalities, and mental retardation [133, 134]. More than 95% of classic RTT cases are caused by mutations in human *MECP2* gene, which encodes the X-linked methyl-CpG binding protein 2 (MeCP2) [135]. By binding to methylated DNA, MeCP2 can read these epigenetic marks in genome and recruit transcriptional repressors and chromatin-modifying enzymes to silence gene expression [136, 137].

MeCP2 is ubiquitous in mammalian tissues and is highly expressed in the brain [138]. Although neurons within the brain contain the highest levels of MeCP2, the expression in these cells is heterogeneous and tightly regulated according to the maturational stage of the individual neurons. The level of MeCP2 is up-regulated in a temporal manner in the course of postnatal neuronal development with the peak in a subpopulation of mature postmitotic neurons [139], suggesting MeCP2 is involved in the maturation of exiting neurons rather than the development of new neurons from precursor cells [140]. Besides neurons in the brain, the expression of MeCP2 has been detected in glial cells [141] and astrocytes [142], and has been shown to be critical for RTT pathogenesis by disrupting support for neuronal dendritic maturation.

MeCP2 consists of a methyl-CpG-binding domain, a transcription repression domain (TRD), two nuclear localization signals, and a C-terminal segment [133]. The methyl-CpG-binding domain specifically binds to 5-methyl-cytosine throughout the genome. The TRD associates with histone deacetylase and transcription silencer corepressor Sin3A. The nuclear localization signals mediate the translocation of the MeCP2 into nucleus, and the C-terminal segment facilitates the binding of MeCP2 to the nucleosome core. These interactions cause histone deacetylation and chromatin condensation, resulting in the repression of transcription [133, 143]. Interestingly, the expression level of MeCP2 in mature neurons is similar to that of core histones, suggesting MeCP2 may play a histone-like role in regulating chromatin and gene expression [144]. Recent studies indicat-

ed that activity-dependent regulation of MeCP2 is also involved in the control of synapse development and behavior [116, 145]. Loss of function of MeCP2 in cells, especially in maturing postmitotic neurons, may cause inappropriate overexpression of genes that are not required, resulting in the potential damaging effect in the maturation of neurons. By targeted disruption of *MECP2* gene in mice, many of neurodevelopmental phenotypes seen in human have been recapitulated [146, 147]. On the other hand, reintroduction of functional MeCP2 can rescue the developmental phenotypes resulted from MeCP2 deficiency [148], suggesting that the damage caused by a lack of MeCP2 in neurons is reversible. However, overexpression of MeCP2 by even 2-fold can cause a progressive neurological disease with cognitive impairment, speech and social problems [149], suggesting that MeCP2 levels must be tightly regulated *in vivo* and that too much as well as too little functional MeCP2 may cause NDs.

A new regulatory mechanism of gene expression by MeCP2 has been reported recently [150]. MeCP2 regulates gene expression at posttranscriptional level by suppressing nuclear microRNA processing. Specifically, MeCP2 binds directly to DGCR8, a critical component of the nuclear microRNA-processing machinery, and interferes with the assembly of Drosha and DGCR8 complex. Protein targets of MeCP2-suppressed miRNAs include CREB, LIMK1, and Pumilio2, which play critical roles in neural development [150]. These findings suggest that the interactions between various factors such as MeCP2 and miRNAs, form a complex network in the regulation of gene expression.

It is important to note that RTT phenotypes can be also caused by other genetic mutations besides *MECP2*, such as *CDKL5* mutations in early onset seizure variant [151] and *FOXG1* mutations in the congenital variant [152]. On the other hand, the same *MECP2* mutation can cause significant variability of phenotypes in classic RTT and even other kind of NDs, such as autism [153, 154], Angelman syndrome (AS) [155], and X-linked mental retardation (XLMR) [156]. This indicates the multiple functions of MeCP2 in neuron maturation and the complex molecular mechanisms of etiology of NDs.

4.3 FXS

FXS is the most common known inherited cause of intellectual disability and ASD, and it typically results from transcriptional silencing of gene *FMR1* (fragile X mental retardation gene) and loss of its product FMRP

(fragile X mental retardation protein) [157]. Epidemiological studies estimated that the prevalence of FXS is 1/5 000 in males and approximately half as many as in females [158, 159]. Besides the moderate to severe intellectual disability and autistic features as mentioned above, FXS is characterized by seizures and/or epileptiform activity, hypersensitivity to sensory stimuli, attention deficit and hyperactivity, motor incoordination, growth abnormalities, sleep disturbances, craniofacial abnormalities, and macroorchidism (see, excellent review [159]). As FXS is the leading monogenetic cause of ASD, accounting for approximately 5% of ASD cases [160], it has been a valuable model for investigating the pathophysiology that may apply to ASD.

In the majority of FXS, the causative mutation is a trinucleotide (CGG) repeat expansion in *FMR1* [161]. In human, the 5'-untranslated region of *FMR1* is a polymorphic CGG repeats with the most common normal length of 30 repeats. However, in FXS patient, this repeat is expended more than 200 (referred to a full mutation), typically 800, leading to hypermethylation and epigenetic silencing of *FMR1* and loss the encoded protein, FMRP. Alleles with an intermediate repeat length (60–200 repeats) are called premutations. Because the premutation alleles are unstable in meiosis, especially in female meiosis, the repeat length often increases from one generation to the next and has the chance to expand into the full mutation and leads to FXS [162–164].

FMRP is a selective mRNA-binding protein [165] and is highly expressed in neurons. It has been estimated that FMRP binds about 4% of total mRNA in the mammalian brain [166]. FMRP acts as a translational repressor to negatively regulate protein synthesis in the brain, especially at synapses in neurons [167]. Loss of FMRP leads to increased translation of FMRP-bound transcripts and impairs normal synaptic plasticity, which is believed to be the molecular basis of intellectual disability in FXS patients [163, 164]. Consistent with this hypothesis, several independent studies provided the view that many symptoms of FXS arise from a modest increase in synaptic protein synthesis [167–169]. Synaptoneurosomes have increased both protein and mRNA levels of microtubule associated protein 1B (MAP1B), calcium/calmodulin-dependent kinase II alpha (α-CaMKII), and activity-regulated cytoskeleton-associated protein (ARC), which play important roles in synaptogenesis and neuroplasticity [164, 167]. During neuronal

development, programmed FMRP expression represses the translation of MAP1B and is required for the accelerated decline of MAP1B level during active synaptogenesis. In *Fmr1* KO neurons, the loss of FMRP results in misregulated MAP1B translation, leading to abnormally increased microtubule stability [168]. Interestingly, the excessive protein synthesis observed in *Fmr1* knockout mice can be reversed by antagonists of mGluR5. Moreover, in these mice, both genetic and pharmacological inhibition of mGluR5 reverses synaptic and behavioral impairments, which are the basis of human clinical trials that aim to test the efficacy of mGluR5 antagonists for the treatment of FXS [159, 170]. There is significant overlap between FMRP targets and ASD candidate genes, such as *NLGN3, NRXN1, SHANK3, PTEN, TSC1* and *NFI* [116, 132, 159], and most of them have been shown to participate in synapse plasticity and some of them have been discussed above.

Although mounting evidence suggests that FMRP functions to negatively regulate protein synthesis, the mechanisms of translational regulation by FMRP are not fully understood. One possible mechanism is that FMRP inhibits translation of its target mRNA by stalling ribosomes and through association with miRNA. Recent study found that FMRP interacts with the coding region of transcripts encoding pre- and postsynaptic proteins and reversibly stalls ribosomes specifically on its target mRNAs, suggesting FMRP dynamically represses translation in a complex consisting of target mRNAs and stalled ribosomes [171]. Moreover, given the majority of FMRP binding was found within coding sequence of mRNA, supporting the original hypothesis that FMRP represses translation by blocking elongation [172]. However, other studies indicated that FMRP may repress translation throughout many phases of translational regulation, including initiation stage [173, 174]. FMRP cooperates with translational machinery either to stall elongation or block initiation, in which the association with miRNA machinery has been shown to be involved. FMRP interacts with members of the RNA-induced silencing complex (RISC), including Argonaute and Dicer [175, 176]. Several specific miRNAs, such as miR-125b and miR132, are selectively associated with FMRP via interaction with members of the RISC [95, 177]. However, how ribosome stalling and miRNA-directed translational repression are spatially and temporally coordinated with each other remains to be investigated.

5 Concluding remarks

During neuronal development, gene expression can be regulated by multiple mechanisms at different levels of the flow of genetic information. By targeting chromatin structure, transcription and translation processes, the regulatory network consisting of transcription regulatory proteins, histone modifications, DNA methylations and miRNAs achieves the exquisite regulation of the neuronal gene expression in response to environmental stimuli at different developmental stages (Fig. 4). Dysregulation of the gene expression during neuronal development has been shown to be implicated in a number of NDs, suggesting the regulation of gene expression plays a crucial role in neuronal development and normal functions.

Currently, ASD is diagnosed entirely on behavioral criteria. To better target the underlying basis of ASD for diagnosis and treatment, considerable progress has been made in the identification of reliable biomarkers in genetics, neuroimaging, gene expression, and measures of the body's metabolism [178–181]. However, as ASD encompass a range of neurodevelopmental conditions that are clinically and etiologically very heterogeneous, there are no reliable biomarkers with enough evidence to support routine clinical use unless medical illness is suspected. On the contrary, some available biomarkers for ASD are regarded doing more harm than good [182, 183]. Thus, we are still so far away to completely conquer these NDs like ASD, which relies on the breakthroughs in understanding the pathological mechanisms underlying these disorders and effective strategies for diagnosis and treatment.

The molecular mechanisms of gene expression during neuronal development will be continually focused on in biomedical research. Besides the classical molecular biological techniques that explore functions of gene/protein individually, approaches based on the next generation sequencing such as genome sequencing, RNA seq and ChIP seq make it possible to view the gene expression and regulation genome-wildly. These techniques greatly facilitate the understanding of the regulatory mechanisms in a global view and accelerate the identification of disease related mutations. The further understanding of the gene regulation in neuronal development under both physiological and pathological conditions may provide new approaches for diagnosis and pharmaceutical treatment of related disorders.

REFERENCES

1　West AE, Griffith EC, Greenberg ME. Regulation of transcription factors by neuronal activity. Nat Rev Neurosci 2002; 3(12): 921–931.

2　Wang VY, Zoghbi HY. Genetic regulation of cerebellar development. Nat Rev Neurosci 2001; 2(7): 484–491.

3　Kilpatrick DL, Wang W, Gronostajski R, Litwack ED. Nuclear factor I and cerebellar granule neuron development: an intrinsic-extrinsic interplay. Cerebellum 2012; 11(1): 41–49.

4　Azevedo FA, Carvalho LR, Grinberg LT, Farfel JM, Ferretti RE, Leite RE, Jacob Filho W, Lent R, Herculano-Houzel S. Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain. J Comp Neurol 2009; 513(5): 532–541.

5　Steuber V, Jaeger D. Modeling the generation of output by the cerebellar nuclei. Neural Netw 2013; 47: 112–119.

6　Voogd J. Cerebellar zones: a personal history. Cerebellum 2011; 10(3): 334–350.

7　Gao Z, van Beugen BJ, De Zeeuw CI. Distributed synergistic plasticity and cerebellar learning. Nat Rev Neurosci 2012; 13(9): 619–635.

8　Schmahmann JD, Caplan D. Cognition, emotion and the cerebellum. Brain 2006; 129(Pt 2): 290–292.

9　Wang X, Patel ND, Hui D, Pal R, Hafez MM, Sayed-Ahmed MM, Al-Yahya AA, Michaelis EK. Gene expression patterns in the hippocampus during the development and aging of Glud1 (Glutamate Dehydrogenase 1) transgenic and wild type mice. BMC Neurosci 2014; 15: 37.

10　Ma L, Wu Y, Qiu Q, Scheerer H, Moran A, Yu CR. A developmental switch of axon targeting in the continuously regenerating mouse olfactory system. Science 2014; 344(6180): 194–197.

11　Wilkinson G, Dennis D, Schuurmans C. Proneural genes in neocortical development. Neuroscience 2013; 253: 256–273.

12　Tuoc TC, Pavlakis E, Tylkowski MA, Stoykova A. Control of cerebral size and thickness. Cell Mol Life Sci 2014; 71(17): 3199–3218.

13　Jung H, Gkogkas CG, Sonenberg N, Holt CE. Remote control of gene function by local translation. Cell 2014; 157(1): 26–40.

14　Jung H, Yoon BC, Holt CE. Axonal mRNA localization and local protein synthesis in nervous system assembly, maintenance and repair. Nat Rev Neurosci 2012; 13(5): 308–324.

15　Leal G, Comprido D, Duarte CB. BDNF-induced local protein synthesis and synaptic plasticity. Neuropharmacology 2014; 76 Pt C: 639–656.

16　West AE, Greenberg ME. Neuronal activity-regulated gene transcription in synapse development and cognitive function. Cold Spring Harb Perspect Biol 2011; 3(6). pii: a005744

17　Hong EJ, West AE, Greenberg ME. Transcriptional control of cognitive development. Curr Opin Neurobiol 2005; 15(1): 21–28.

18　Alder J, Cho NK, Hatten ME. Embryonic precursor cells from the rhombic lip are specified to a cerebellar granule neuron identity. Neuron 1996; 17(3): 389–399.

19　Wechsler-Reya RJ. Analysis of gene expression in the normal and malignant cerebellum. Recent Prog Horm Res 2003; 58: 227–248.

20　Komuro H, Yacubova E, Rakic P. Mode and tempo of tangential cell migration in the cerebellar external granular layer. J Neurosci 2001; 21(2): 527–540.

21　Altman J. Postnatal development of the cerebellar cortex in the rat. 3. Maturation of the components of the granular layer. J Comp Neurol 1972; 145(4): 465–513.

22　Kawauchi D, Saito T. Transcriptional cascade from Math1 to Mbh1 and Mbh2 is required for cerebellar granule cell differentiation. Dev Biol 2008; 322(2): 345–354.

23　Wang W, Crandall JE, Litwack ED, Gronostajski RM, Kilpatrick DL. Targets of the nuclear factor I regulon involved in early and late development of postmitotic cerebellar granule neurons. J Neurosci Res 2010; 88(2): 258–265.

24　Okazawa M, Abe H, Katsukawa M, Iijima K, Kiwada T, Nakanishi S. Role of calcineurin signaling in membrane potential-regulated maturation of cerebellar granule cells. J Neurosci 2009; 29(9): 2938–2947.

25　Mellor JR, Merlo D, Jones A, Wisden W, Randall AD. Mouse cerebellar granule cell differentiation: electrical activity regulates the GABA$_A$ receptor alpha 6 subunit gene. J Neurosci 1998; 18(8): 2822–2833.

26　Wang W, Stock RE, Gronostajski RM, Wong YW, Schachner M, Kilpatrick DL. A role for nuclear factor I in the intrinsic control of cerebellar granule neuron gene expression. J Biol Chem 2004; 279(51): 53491–53497.

27　Ding B, Wang W, Selvakumar T, Xi HS, Zhu H, Chow CW, Horton JD, Gronostajski RM, Kilpatrick DL. Temporal regulation of nuclear factor one occupancy by calcineurin/NFAT governs a voltage-sensitive developmental switch in late maturing neurons. J Neurosci 2013; 33(7): 2860–2872.

28　Chrivia JC, Kwok RP, Lamb N, Hagiwara M, Montminy MR, Goodman RH. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 1993; 365(6449): 855–859.

29　Lyons GE, Micales BK, Schwarz J, Martin JF, Olson EN. Expression of mef2 genes in the mouse central nervous

system suggests a role in neuronal maturation. J Neurosci 1995; 15(8): 5727–5738.

30 Flavell SW, Cowan CW, Kim TK, Greer PL, Lin Y, Paradis S, Griffith EC, Hu LS, Chen C, Greenberg ME. Activity-dependent regulation of MEF2 transcription factors suppresses excitatory synapse number. Science 2006; 311(5763): 1008–1012.

31 Dietrich JB. The MEF2 family and the brain: from molecules to memory. Cell Tissue Res 2013; 352(2): 179–190.

32 Rashid AJ, Cole CJ, Josselyn SA. Emerging roles for MEF2 transcription factors in memory. Genes Brain Behav 2014; 13(1): 118–125.

33 Shalizi A, Gaudilliere B, Yuan Z, Stegmuller J, Shirogane T, Ge Q, Tan Y, Schulman B, Harper JW, Bonni A. A calcium-regulated MEF2 sumoylation switch controls postsynaptic differentiation. Science 2006; 311(5763): 1012–1017.

34 Graef IA, Wang F, Charron F, Chen L, Neilson J, Tessier-Lavigne M, Crabtree GR. Neurotrophins and netrins require calcineurin/NFAT signaling to stimulate outgrowth of embryonic axons. Cell 2003; 113(5): 657–670.

35 Nguyen T, Di Giovanni S. NFAT signaling in neural development and axon growth. Int J Dev Neurosci 2008; 26(2): 141–145.

36 Graef IA, Chen F, Chen L, Kuo A, Crabtree GR. Signals transduced by Ca^{2+}/calcineurin and NFATc3/c4 pattern the developing vasculature. Cell 2001; 105(7): 863–875.

37 Okamura H, Garcia-Rodriguez C, Martinson H, Qin J, Virshup DM, Rao A. A conserved docking motif for CK1 binding controls the nuclear localization of NFAT1. Mol Cell Biol 2004; 24(10): 4184–4195.

38 Im SH, Rao A. Activation and deactivation of gene expression by Ca^{2+}/calcineurin-NFAT-mediated signaling. Mol Cells 2004; 18(1): 1–9.

39 Gronostajski RM. Roles of the NFI/CTF gene family in transcription and development. Gene 2000; 249(1–2): 31–45.

40 Mason S, Piper M, Gronostajski RM, Richards LJ. Nuclear factor one transcription factors in CNS development. Mol Neurobiol 2009; 39(1): 10–23.

41 Plachez C, Lindwall C, Sunn N, Piper M, Moldrich RX, Campbell CE, Osinski JM, Gronostajski RM, Richards LJ. Nuclear factor I gene expression in the developing forebrain. J Comp Neurol 2008; 508(3): 385–401.

42 Wang W, Mullikin-Kilpatrick D, Crandall JE, Gronostajski RM, Litwack ED, Kilpatrick DL. Nuclear factor I coordinates multiple phases of cerebellar granule cell development via regulation of cell adhesion molecules. J Neurosci 2007; 27(23): 6115–6127.

43 Wang W, Shin Y, Shi M, Kilpatrick DL. Temporal control of a dendritogenesis-linked gene via REST-dependent

regulation of nuclear factor I occupancy. Mol Biol Cell 2011; 22(6): 868–879.

44 Abe H, Okazawa M, Nakanishi S. The Etv1/Er81 transcription factor orchestrates activity-dependent gene regulation in the terminal maturation program of cerebellar granule cells. Proc Natl Acad Sci U S A 2011; 108(30): 12497–12502.

45 Abe H, Okazawa M, Nakanishi S. Gene regulation via excitation and BDNF is mediated by induction and phosphorylation of the Etv1 transcription factor in cerebellar granule cells. Proc Natl Acad Sci U S A 2012; 109(22): 8734–8739.

46 Qiu Z, Ghosh A. A brief history of neuronal gene expression: regulatory mechanisms and cellular consequences. Neuron 2008; 60(3): 449–455.

47 Maze I, Noh KM, Allis CD. Histone regulation in the CNS: basic principles of epigenetic plasticity. Neuropsychopharmacology 2013; 38(1): 3–22.

48 Schratt GM, Tuebing F, Nigh EA, Kane CG, Sabatini ME, Kiebler M, Greenberg ME. A brain-specific microRNA regulates dendritic spine development. Nature 2006; 439(7074): 283–289.

49 Bird A. Perceptions of epigenetics. Nature 2007; 447(7143): 396–398.

50 Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 2007; 447(7143): 425–432.

51 Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997; 389(6648): 251–260.

52 Nightingale KP, O'Neill LP, Turner BM. Histone modifications: signalling receptors and potential elements of a heritable epigenetic code. Curr Opin Genet Dev 2006; 16(2): 125–136.

53 Dulac C. Brain function and chromatin plasticity. Nature 2010; 465(7299): 728–735.

54 Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996; 87(5): 953–959.

55 Brownell JE, Zhou J, Ranalli T, Kobayashi R, Edmondson DG, Roth SY, Allis CD. Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation. Cell 1996; 84(6): 843–851.

56 Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 1996; 272(5260): 408–411.

57 Goldberg AD, Allis CD, Bernstein E. Epigenetics: a landscape takes shape. Cell 2007; 128(4): 635–638.

58 Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, Gao J, Nieland TJ, Zhou Y, Wang X, Mazitschek

R, Bradner JE, DePinho RA, Jaenisch R, Tsai LH. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 2009; 459(7243): 55–60.

59   Roh TY, Cuddapah S, Zhao K. Active chromatin domains are defined by acetylation islands revealed by genome-wide mapping. Genes Dev 2005; 19(5): 542–552.

60   Tsukada Y, Fang J, Erdjument-Bromage H, Warren ME, Borchers CH, Tempst P, Zhang Y. Histone demethylation by a family of JmjC domain-containing proteins. Nature 2006; 439(7078): 811–816.

61   Shinkai Y, Tachibana M. H3K9 methyltransferase G9a and the related molecule GLP. Genes Dev 2011; 25(8): 781–788.

62   Kouzarides T. Chromatin modifications and their function. Cell 2007; 128(4): 693–705.

63   Klose RJ, Sarraf SA, Schmiedeberg L, McDermott SM, Stancheva I, Bird AP. DNA binding selectivity of MeCP2 due to a requirement for A/T sequences adjacent to methyl-CpG. Mol Cell 2005; 19(5): 667–678.

64   Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacology 2013; 38(1): 23–38.

65   Saxonov S, Berg P, Brutlag DL. A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci U S A 2006; 103(5): 1412–1417.

66   Ramirez-Carrozzi VR, Braas D, Bhatt DM, Cheng CS, Hong C, Doty KR, Black JC, Hoffmann A, Carey M, Smale ST. A unifying model for the selective regulation of inducible transcription by CpG islands and nucleosome remodeling. Cell 2009; 138(1): 114–128.

67   Mohn F, Weber M, Rebhan M, Roloff TC, Richter J, Stadler MB, Bibel M, Schubeler D. Lineage-specific polycomb targets and *de novo* DNA methylation define restriction and potential of neuronal progenitors. Mol Cell 2008; 30(6): 755–766.

68   Meissner A, Mikkelsen TS, Gu H, Wernig M, Hanna J, Sivachenko A, Zhang X, Bernstein BE, Nusbaum C, Jaffe DB, Gnirke A, Jaenisch R, Lander ES. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 2008; 454(7205): 766–770.

69   Feng J, Fouse S, Fan G. Epigenetic regulation of neural gene expression and neuronal function. Pediatr Res 2007; 61(5 Pt 2): 58R-63R.

70   Middeldorp J, Hol EM. GFAP in health and disease. Prog Neurobiol 2011; 93(3): 421–443.

71   Takizawa T, Nakashima K, Namihira M, Ochiai W, Uemura A, Yanagisawa M, Fujita N, Nakao M, Taga T. DNA methylation is a critical cell-intrinsic determinant of astrocyte differentiation in the fetal brain. Dev Cell 2001; 1(6): 749–758.

72   Teter B, Rozovsky I, Krohn K, Anderson C, Osterburg H, Finch C. Methylation of the glial fibrillary acidic protein gene shows novel biphasic changes during brain development. Glia 1996; 17(3): 195–205.

73   Fan G, Martinowich K, Chin MH, He F, Fouse SD, Hutnick L, Hattori D, Ge W, Shen Y, Wu H, ten Hoeve J, Shuai K, Sun YE. DNA methylation controls the timing of astrogliogenesis through regulation of JAK-STAT signaling. Development 2005; 132(15): 3345–3356.

74   Hutnick LK, Golshani P, Namihira M, Xue Z, Matynia A, Yang XW, Silva AJ, Schweizer FE, Fan G. DNA hypomethylation restricted to the murine forebrain induces cortical degeneration and impairs postnatal neuronal maturation. Hum Mol Genet 2009; 18(15): 2875–2888.

75   Levine M, Tjian R. Transcription regulation and animal diversity. Nature 2003; 424(6945): 147–151.

76   Wang W, Cote J, Xue Y, Zhou S, Khavari PA, Biggar SR, Muchardt C, Kalpana GV, Goff SP, Yaniv M, Workman JL, Crabtree GR. Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. EMBO J 1996; 15(19): 5370–5382.

77   Lessard J, Wu JI, Ranish JA, Wan M, Winslow MM, Staahl BT, Wu H, Aebersold R, Graef IA, Crabtree GR. An essential switch in subunit composition of a chromatin remodeling complex during neural development. Neuron 2007; 55(2): 201–215.

78   Wu JI, Lessard J, Olave IA, Qiu Z, Ghosh A, Graef IA, Crabtree GR. Regulation of dendritic development by neuron-specific chromatin remodeling complexes. Neuron 2007; 56(1): 94–108.

79   Yoo AS, Staahl BT, Chen L, Crabtree GR. MicroRNA-mediated switching of chromatin-remodelling complexes in neural development. Nature 2009; 460(7255): 642–646.

80   Aizawa H, Hu SC, Bobb K, Balakrishnan K, Ince G, Gurevich I, Cowan M, Ghosh A. Dendrite development regulated by CREST, a calcium-regulated transcriptional activator. Science 2004; 303(5655): 197–202.

81   Qiu Z, Ghosh A. A calcium-dependent switch in a CREST-BRG1 complex regulates activity-dependent gene expression. Neuron 2008; 60(5): 775–787.

82   Klein ME, Impey S, Goodman RH. Role reversal: the regulation of neuronal gene expression by microRNAs. Curr Opin Neurobiol 2005; 15(5): 507–513.

83   Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 2005; 6(5): 376–385.

84   Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ. Processing of primary microRNAs by the Microprocessor complex. Nature 2004; 432(7014): 231–235.

85   Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin

RNAs. Genes Dev 2003; 17(24): 3011–3016.

86 Schratt G. microRNAs at the synapse. Nat Rev Neurosci 2009; 10(12): 842–849.

87 Karres JS, Hilgers V, Carrera I, Treisman J, Cohen SM. The conserved microRNA miR-8 tunes atrophin levels to prevent neurodegeneration in Drosophila. Cell 2007; 131(1): 136–145.

88 Davis TH, Cuellar TL, Koch SM, Barker AJ, Harfe BD, McManus MT, Ullian EM. Conditional loss of Dicer disrupts cellular and tissue morphogenesis in the cortex and hippocampus. J Neurosci 2008; 28(17): 4322–4330.

89 Cheng LC, Pastrana E, Tavazoie M, Doetsch F. miR-124 regulates adult neurogenesis in the subventricular zone stem cell niche. Nat Neurosci 2009; 12(4): 399–408.

90 Zhao C, Sun G, Li S, Shi Y. A feedback regulatory loop involving microRNA-9 and nuclear receptor TLX in neural stem cell fate determination. Nat Struct Mol Biol 2009; 16(4): 365–371.

91 Magill ST, Cambronne XA, Luikart BW, Lioy DT, Leighton BH, Westbrook GL, Mandel G, Goodman RH. microRNA-132 regulates dendritic growth and arborization of newborn neurons in the adult hippocampus. Proc Natl Acad Sci U S A 2010; 107(47): 20382–20387.

92 Gaughwin P, Ciesla M, Yang H, Lim B, Brundin P. Stage-specific modulation of cortical neuronal development by Mmu-miR-134. Cereb Cortex 2011; 21(8): 1857–1869.

93 Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M, Vandenberg SR, Ginzinger DG, James CD, Costello JF, Bergers G, Weiss WA, Alvarez-Buylla A, Hodgson JG. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 2008; 6: 14.

94 Siegel G, Obernosterer G, Fiore R, Oehmen M, Bicker S, Christensen M, Khudayberdiev S, Leuschner PF, Busch CJ, Kane C, Hubel K, Dekker F, Hedberg C, Rengarajan B, Drepper C, Waldmann H, Kauppinen S, Greenberg ME, Draguhn A, Rehmsmeier M, Martinez J, Schratt GM. A functional screen implicates microRNA-138-dependent regulation of the depalmitoylation enzyme APT1 in dendritic spine morphogenesis. Nat Cell Biol 2009; 11(6): 705–716.

95 Edbauer D, Neilson JR, Foster KA, Wang CF, Seeburg DP, Batterton MN, Tada T, Dolan BM, Sharp PA, Sheng M. Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132. Neuron 2010; 65(3): 373–384.

96 Bruno IG, Karam R, Huang L, Bhardwaj A, Lou CH, Shum EY, Song HW, Corbett MA, Gifford WD, Gecz J, Pfaff SL, Wilkinson MF. Identification of a microRNA that activates gene expression by repressing nonsense-mediated RNA decay. Mol Cell 2011; 42(4): 500–510.

97 Abdelmohsen K, Hutchison ER, Lee EK, Kuwano Y, Kim MM, Masuda K, Srikantan S, Subaran SS, Marasa BS, Mattson MP, Gorospe M. miR-375 inhibits differentiation of neurites by lowering HuD levels. Mol Cell Biol 2010; 30(17): 4197–4210.

98 Olde Loohuis NF, Kos A, Martens GJ, Van Bokhoven H, Nadif Kasri N, Aschrafi A. MicroRNA networks direct neuronal development and plasticity. Cell Mol Life Sci 2012; 69(1): 89–102.

99 Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002; 12(9): 735–739.

100 Yu JY, Chung KH, Deo M, Thompson RC, Turner DL. MicroRNA miR-124 regulates neurite outgrowth during neuronal differentiation. Exp Cell Res 2008; 314(14): 2618–2633.

101 Shibata M, Kurokawa D, Nakao H, Ohmura T, Aizawa S. MicroRNA-9 modulates Cajal-Retzius cell differentiation by suppressing Foxg1 expression in mouse medial pallium. J Neurosci 2008; 28(41): 10415–10421.

102 Shibata M, Nakao H, Kiyonari H, Abe T, Aizawa S. MicroRNA-9 regulates neurogenesis in mouse telencephalon by targeting multiple transcription factors. J Neurosci 2011; 31(9): 3407–3422.

103 Impey S, Davare M, Lesiak A, Fortin D, Ando H, Varlamova O, Obrietan K, Soderling TR, Goodman RH, Wayman GA. An activity-induced microRNA controls dendritic spine formation by regulating Rac1-PAK signaling. Mol Cell Neurosci 2010; 43(1): 146–156.

104 Wayman GA, Davare M, Ando H, Fortin D, Varlamova O, Cheng HY, Marks D, Obrietan K, Soderling TR, Goodman RH, Impey S. An activity-regulated microRNA controls dendritic plasticity by down-regulating p250GAP. Proc Natl Acad Sci U S A 2008; 105(26): 9093–9098.

105 Walsh CA, Morrow EM, Rubenstein JL. Autism and brain development. Cell 2008; 135(3): 396–400.

106 Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res 2009; 65(6): 591–598.

107 Mefford HC, Batshaw ML, Hoffman EP. Genomics, intellectual disability, and autism. N Engl J Med 2012; 366(8): 733–743.

108 Wong VC, Hui SL. Epidemiological study of autism spectrum disorder in China. J Child Neurol 2008; 23(1): 67–72.

109 Zhang X, Ji CY. Autism and mental retardation of young children in China. Biomed Environ Sci 2005; 18(5): 334–340.

110 Huang AX, Jia M, Wheeler JJ. Children with autism in the People's Republic of China: diagnosis, legal Issues, and

educational services. J Autism Dev Disord 2013; 43(9): 1991–2001.

111 Wan Y, Hu Q, Li T, Jiang L, Du Y, Feng L, Wong JC, Li C. Prevalence of autism spectrum disorders among children in China: a systematic review. Shanghai Arch Psychiatry 2013; 25(2): 70–80.

112 Banerjee S, Riordan M, Bhat MA. Genetic aspects of autism spectrum disorders: insights from animal models. Front Cell Neurosci 2014; 8: 58.

113 Matuszek G, Talebizadeh Z. Autism Genetic Database (AGD): a comprehensive database including autism sus-ceptibility gene-CNVs integrated with known noncoding RNAs and fragile sites. BMC Med Genet 2009; 10: 102.

114 Folstein SE, Rosen-Sheidley B. Genetics of autism: com-plex aetiology for a heterogeneous disorder. Nat Rev Genet 2001; 2(12): 943–955.

115 Betancur C. Etiological heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still counting. Brain Res 2011; 1380: 42–77.

116 Ebert DH, Greenberg ME. Activity-dependent neuronal signalling and autism spectrum disorder. Nature 2013; 493(7432): 327–337.

117 Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, Skaug J, Shago M, Moessner R, Pinto D, Ren Y, Thiruva-hindrapduram B, Fiebig A, Schreiber S, Friedman J, Ketelaars CE, Vos YJ, Ficicioglu C, Kirkpatrick S, Nicolson R, Sloman L, Summers A, Gibbons CA, Teebi A, Chitayat D, Weksberg R, Thompson A, Vardy C, Crosbie V, Lus-combe S, Baatjes R, Zwaigenbaum L, Roberts W, Fernan-dez B, Szatmari P, Scherer SW. Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet 2008; 82(2): 477–488.

118 Jamain S, Quach H, Betancur C, Rastam M, Colineaux C, Gillberg IC, Soderstrom H, Giros B, Leboyer M, Gillberg C, Bourgeron T. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet 2003; 34(1): 27–29.

119 Varoqueaux F, Aramuni G, Rawson RL, Mohrmann R, Missler M, Gottmann K, Zhang W, Sudhof TC, Brose N. Neuroligins determine synapse maturation and function. Neuron 2006; 51(6): 741–754.

120 Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Raynaud M, Ronce N, Lemonnier E, Calvas P, Laudier B, Chelly J, Fryns JP, Ropers HH, Hamel BC, Andres C, Barthelemy C, Moraine C, Briault S. X-linked mental retardation and autism are associated with a mutation in the NLGN4 gene, a member of the neuroligin family. Am J Hum Genet 2004; 74(3): 552–557.

121 Durand CM, Betancur C, Boeckers TM, Bockmann J, Chaste P, Fauchereau F, Nygren G, Rastam M, Gillberg IC, Anckarsater H, Sponheim E, Goubran-Botros H, Delorme R, Chabane N, Mouren-Simeoni MC, de Mas P, Bieth E, Roge B, Heron D, Burglen L, Gillberg C, Leboyer M, Bourgeron T. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet 2007; 39(1): 25–27.

122 Sanders SJ, Ercan-Sencicek AG, Hus V, Luo R, Murtha MT, Moreno-De-Luca D, Chu SH, Moreau MP, Gupta AR, Thomson SA, Mason CE, Bilguvar K, Celestino-Soper PB, Choi M, Crawford EL, Davis L, Wright NR, Dhodapkar RM, DiCola M, DiLullo NM, Fernandez TV, Field-ing-Singh V, Fishman DO, Frahm S, Garagaloyan R, Goh GS, Kammela S, Klei L, Lowe JK, Lund SC, McGrew AD, Meyer KA, Moffat WJ, Murdoch JD, O'Roak BJ, Ober GT, Pottenger RS, Raubeson MJ, Song Y, Wang Q, Yaspan BL, Yu TW, Yurkiewicz IR, Beaudet AL, Cantor RM, Cur-land M, Grice DE, Gunel M, Lifton RP, Mane SM, Martin DM, Shaw CA, Sheldon M, Tischfield JA, Walsh CA, Mor-row EM, Ledbetter DH, Fombonne E, Lord C, Martin CL, Brooks AI, Sutcliffe JS, Cook EH Jr, Geschwind D, Roeder K, Devlin B, State MW. Multiple recurrent *de novo* CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. Neuron 2011; 70(5): 863–885.

123 Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, Willsey AJ, Ercan-Sencicek AG, DiLullo NM, Parikshak NN, Stein JL, Walker MF, Ober GT, Teran NA, Song Y, El-Fishawy P, Murtha RC, Choi M, Overton JD, Bjornson RD, Carriero NJ, Meyer KA, Bilguvar K, Mane SM, Sestan N, Lifton RP, Gunel M, Roeder K, Geschwind DH, Devlin B, State MW. *De novo* mutations revealed by whole-exome sequencing are strongly associ-ated with autism. Nature 2012; 485(7397): 237–241.

124 Neale BM, Kou Y, Liu L, Ma'ayan A, Samocha KE, Sabo A, Lin CF, Stevens C, Wang LS, Makarov V, Polak P, Yoon S, Maguire J, Crawford EL, Campbell NG, Geller ET, Val-ladares O, Schafer C, Liu H, Zhao T, Cai G, Lihm J, Dan-nenfelser R, Jabado O, Peralta Z, Nagaswamy U, Muzny D, Reid JG, Newsham I, Wu Y, Lewis L, Han Y, Voight BF, Lim E, Rossin E, Kirby A, Flannick J, Fromer M, Shakir K, Fennell T, Garimella K, Banks E, Poplin R, Gabriel S, DePristo M, Wimbish JR, Boone BE, Levy SE, Betancur C, Sunyaev S, Boerwinkle E, Buxbaum JD, Cook EH Jr, Devlin B, Gibbs RA, Roeder K, Schellenberg GD, Sutcliffe JS, Daly MJ. Patterns and rates of exonic *de novo* muta-tions in autism spectrum disorders. Nature 2012; 485(7397): 242–245.

125 O'Roak BJ, Vives L, Girirajan S, Karakoc E, Krumm N, Coe BP, Levy R, Ko A, Lee C, Smith JD, Turner EH, Stanaway IB, Vernot B, Malig M, Baker C, Reilly B, Akey

JM, Borenstein E, Rieder MJ, Nickerson DA, Bernier R, Shendure J, Eichler EE. Sporadic autism exomes reveal a highly interconnected protein network of *de novo* mutations. Nature 2012; 485(7397): 246–250.

126　Shulha HP, Cheung I, Whittle C, Wang J, Virgil D, Lin CL, Guo Y, Lessard A, Akbarian S, Weng Z. Epigenetic signatures of autism: trimethylated H3K4 landscapes in prefrontal neurons. Arch Gen Psychiatry 2012; 69(3): 314–324.

127　Chubykin AA, Atasoy D, Etherton MR, Brose N, Kavalali ET, Gibson JR, Sudhof TC. Activity-dependent validation of excitatory versus inhibitory synapses by neuroligin-1 versus neuroligin-2. Neuron 2007; 54(6): 919–931.

128　Morrow EM, Yoo SY, Flavell SW, Kim TK, Lin Y, Hill RS, Mukaddes NM, Balkhy S, Gascon G, Hashmi A, Al-Saad S, Ware J, Joseph RM, Greenblatt R, Gleason D, Ertelt JA, Apse KA, Bodell A, Partlow JN, Barry B, Yao H, Markianos K, Ferland RJ, Greenberg ME, Walsh CA. Identifying autism loci and genes by tracing recent shared ancestry. Science 2008; 321(5886): 218–223.

129　Flavell SW, Kim TK, Gray JM, Harmin DA, Hemberg M, Hong EJ, Markenscoff-Papadimitriou E, Bear DM, Greenberg ME. Genome-wide analysis of MEF2 transcriptional program reveals synaptic target genes and neuronal activity-dependent polyadenylation site selection. Neuron 2008; 60(6): 1022–1038.

130　Lin Y, Bloodgood BL, Hauser JL, Lapan AD, Koon AC, Kim TK, Hu LS, Malik AN, Greenberg ME. Activity-dependent regulation of inhibitory synapse development by Npas4. Nature 2008; 455(7217): 1198–1204.

131　Persico AM, Napolioni V. Autism genetics. Behav Brain Res 2013; 251: 95–112.

132　Santini E, Klann E. Reciprocal signaling between translational control pathways and synaptic proteins in autism spectrum disorders. Sci Signal 2014; 7(349): re10.

133　Bienvenu T, Chelly J. Molecular genetics of Rett syndrome: when DNA methylation goes unrecognized. Nat Rev Genet 2006; 7(6): 415–426.

134　Chahrour M, Zoghbi HY. The story of Rett syndrome: from clinic to neurobiology. Neuron 2007; 56(3): 422–437.

135　Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 1999; 23(2): 185–188.

136　Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J, Wolffe AP. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998; 19(2): 187–191.

137　Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP, Kouzarides T. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 2003; 278(6): 4035–4040.

138　Shahbazian MD, Antalffy B, Armstrong DL, Zoghbi HY. Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation. Hum Mol Genet 2002; 11(2): 115–124.

139　Balmer D, Goldstine J, Rao YM, LaSalle JM. Elevated methyl-CpG-binding protein 2 expression is acquired during postnatal human brain development and is correlated with alternative polyadenylation. J Mol Med (Berl) 2003; 81(1): 61–68.

140　Gonzales ML, LaSalle JM. The role of MeCP2 in brain development and neurodevelopmental disorders. Curr Psychiatry Rep 2010; 12(2): 127–134.

141　Ballas N, Lioy DT, Grunseich C, Mandel G. Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology. Nat Neurosci 2009; 12(3): 311–317.

142　Maezawa I, Swanberg S, Harvey D, LaSalle JM, Jin LW. Rett syndrome astrocytes are abnormal and spread MeCP2 deficiency through gap junctions. J Neurosci 2009; 29(16): 5051–5061.

143　Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998; 393(6683): 386–389.

144　Skene PJ, Illingworth RS, Webb S, Kerr AR, James KD, Turner DJ, Andrews R, Bird AP. Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. Mol Cell 2010; 37(4): 457–468.

145　Cohen S, Gabel HW, Hemberg M, Hutchinson AN, Sadacca LA, Ebert DH, Harmin DA, Greenberg RS, Verdine VK, Zhou Z, Wetsel WC, West AE, Greenberg ME. Genome-wide activity-dependent MeCP2 phosphorylation regulates nervous system development and function. Neuron 2011; 72(1): 72–85.

146　Chen RZ, Akbarian S, Tudor M, Jaenisch R. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet 2001; 27(3): 327–331.

147　Guy J, Hendrich B, Holmes M, Martin JE, Bird A. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet 2001; 27(3): 322–326.

148　Guy J, Gan J, Selfridge J, Cobb S, Bird A. Reversal of neurological defects in a mouse model of Rett syndrome. Science 2007; 315(5815): 1143–1147.

149　Collins AL, Levenson JM, Vilaythong AP, Richman R, Armstrong DL, Noebels JL, David Sweatt J, Zoghbi HY. Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum Mol Genet 2004; 13(21): 2679–2689.

150 Cheng TL, Wang Z, Liao Q, Zhu Y, Zhou WH, Xu W, Qiu Z. MeCP2 suppresses nuclear microRNA processing and dendritic growth by regulating the DGCR8/Drosha complex. Dev Cell 2014; 28(5): 547–560.

151 Lin C, Franco B, Rosner MR. CDKL5/Stk9 kinase inactivation is associated with neuronal developmental disorders. Hum Mol Genet 2005; 14(24): 3775–3786.

152 Ariani F, Hayek G, Rondinella D, Artuso R, Mencarelli MA, Spanhol-Rosseto A, Pollazzon M, Buoni S, Spiga O, Ricciardi S, Meloni I, Longo I, Mari F, Broccoli V, Zappella M, Renieri A. FOXG1 is responsible for the congenital variant of Rett syndrome. Am J Hum Genet 2008; 83(1): 89–93.

153 Loat CS, Curran S, Lewis CM, Duvall J, Geschwind D, Bolton P, Craig IW. Methyl-CpG-binding protein 2 polymorphisms and vulnerability to autism. Genes Brain Behav 2008; 7(7): 754–760.

154 Ramocki MB, Peters SU, Tavyev YJ, Zhang F, Carvalho CM, Schaaf CP, Richman R, Fang P, Glaze DG, Lupski JR, Zoghbi HY. Autism and other neuropsychiatric symptoms are prevalent in individuals with MeCP2 duplication syndrome. Ann Neurol 2009; 66(6): 771–782.

155 Watson P, Black G, Ramsden S, Barrow M, Super M, Kerr B, Clayton-Smith J. Angelman syndrome phenotype associated with mutations in MECP2, a gene encoding a methyl CpG binding protein. J Med Genet 2001; 38(4): 224–228.

156 Lugtenberg D, Kleefstra T, Oudakker AR, Nillesen WM, Yntema HG, Tzschach A, Raynaud M, Rating D, Journel H, Chelly J, Goizet C, Lacombe D, Pedespan JM, Echenne B, Tariverdian G, O'Rourke D, King MD, Green A, van Kogelenberg M, Van Esch H, Gecz J, Hamel BC, van Bokhoven H, de Brouwer AP. Structural variation in Xq28: MECP2 duplications in 1% of patients with unexplained XLMR and in 2% of male patients with severe encephalopathy. Eur J Hum Genet 2009; 17(4): 444–453.

157 Garber KB, Visootsak J, Warren ST. Fragile X syndrome. Eur J Hum Genet 2008; 16(6): 666–672.

158 Coffee B, Keith K, Albizua I, Malone T, Mowrey J, Sherman SL, Warren ST. Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am J Hum Genet 2009; 85(4): 503–514.

159 Bhakar AL, Dolen G, Bear MF. The pathophysiology of fragile X (and what it teaches us about synapses). Annu Rev Neurosci 2012; 35: 417–443.

160 Budimirovic DB, Kaufmann WE. What can we learn about autism from studying fragile X syndrome? Dev Neurosci 2011; 33(5): 379–394.

161 Verkerk AJ, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pizzuti A, Reiner O, Richards S, Victoria MF, Zhang FP, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991; 65(5): 905–914.

162 Fu YH, Kuhl DP, Pizzuti A, Pieretti M, Sutcliffe JS, Richards S, Verkerk AJ, Holden JJ, Fenwick RG Jr, Warren ST, et al. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 1991; 67(6): 1047–1058.

163 Wang T, Bray SM, Warren ST. New perspectives on the biology of fragile X syndrome. Curr Opin Genet Dev 2012; 22(3): 256–263.

164 Bassell GJ, Warren ST. Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 2008; 60(2): 201–214.

165 Ashley CT Jr, Wilkinson KD, Reines D, Warren ST. FMR1 protein: conserved RNP family domains and selective RNA binding. Science 1993; 262(5133): 563–566.

166 Brown V, Jin P, Ceman S, Darnell JC, O'Donnell WT, Tenenbaum SA, Jin X, Feng Y, Wilkinson KD, Keene JD, Darnell RB, Warren ST. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 2001; 107(4): 477–487.

167 Zalfa F, Giorgi M, Primerano B, Moro A, Di Penta A, Reis S, Oostra B, Bagni C. The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. Cell 2003; 112(3): 317–327.

168 Lu R, Wang H, Liang Z, Ku L, O'Donnell W T, Li W, Warren ST, Feng Y. The fragile X protein controls microtubule-associated protein 1B translation and microtubule stability in brain neuron development. Proc Natl Acad Sci U S A 2004; 101(42): 15201–15206.

169 Muddashetty RS, Kelic S, Gross C, Xu M, Bassell GJ. Dysregulated metabotropic glutamate receptor-dependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome. J Neurosci 2007; 27(20): 5338–5348.

170 Dolen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, Chattarji S, Bear MF. Correction of fragile X syndrome in mice. Neuron 2007; 56(6): 955–962.

171 Darnell JC, Van Driesche SJ, Zhang C, Hung KY, Mele A, Fraser CE, Stone EF, Chen C, Fak JJ, Chi SW, Licatalosi DD, Richter JD, Darnell RB. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 2011; 146(2): 247–261.

172 Stefani G, Fraser CE, Darnell JC, Darnell RB. Fragile X mental retardation protein is associated with translating polyribosomes in neuronal cells. J Neurosci 2004; 24(33): 7272–7276.

173 Napoli I, Mercaldo V, Boyl PP, Eleuteri B, Zalfa F, De Rubeis S, Di Marino D, Mohr E, Massimi M, Falconi M, Witke W, Costa-Mattioli M, Sonenberg N, Achsel T, Bagni C. The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP. Cell 2008; 134(6): 1042–1054.

174 Lacoux C, Di Marino D, Boyl PP, Zalfa F, Yan B, Ciotti MT, Falconi M, Urlaub H, Achsel T, Mougin A, Caizergues-Ferrer M, Bagni C. BC1-FMRP interaction is modulated by 2'-O-methylation: RNA-binding activity of the tudor domain and translational regulation at synapses. Nucleic Acids Res 2012; 40(9): 4086–4096.

175 Didiot MC, Subramanian M, Flatter E, Mandel JL, Moine H. Cells lacking the fragile X mental retardation protein (FMRP) have normal RISC activity but exhibit altered stress granule assembly. Mol Biol Cell 2009; 20(1): 428–437.

176 Jin P, Zarnescu DC, Ceman S, Nakamoto M, Mowrey J, Jongens TA, Nelson DL, Moses K, Warren ST. Biochemical and genetic interaction between the fragile X mental retardation protein and the microRNA pathway. Nat Neurosci 2004; 7(2): 113–117.

177 Muddashetty RS, Nalavadi VC, Gross C, Yao X, Xing L, Laur O, Warren ST, Bassell GJ. Reversible inhibition of PSD-95 mRNA translation by miR-125a, FMRP phosphorylation, and mGluR signaling. Mol Cell 2011; 42(5): 673–688.

178 Jeste SS, Geschwind DH. Disentangling the heterogeneity of autism spectrum disorder through genetic findings. Nat Rev Neurol 2014; 10(2): 74–81.

179 West PR, Amaral DG, Bais P, Smith AM, Egnash LA, Ross ME, Palmer JA, Fontaine BR, Conard KR, Corbett BA, Cezar GG, Donley EL, Burrier RE. Metabolomics as a tool for discovery of biomarkers of autism spectrum disorder in the blood plasma of children. PLoS One 2014; 9(11): e112445.

180 Tylee DS, Chandler SD, Nievergelt CM, Liu X, Pazol J, Woelk CH, Lohr JB, Kremen WS, Baker DG, Glatt SJ, Tsuang MT; Marine Resiliency Study Investigators. Blood-based gene-expression biomarkers of post-traumatic stress disorder among deployed marines: A pilot study. Psychoneuroendocrinology 2015; 51: 472–494.

181 Goldani AA, Downs SR, Widjaja F, Lawton B, Hendren RL. Biomarkers in autism. Front Psychiatry 2014; 5: 100.

182 Anderson GM. Autism biomarkers: challenges, pitfalls and possibilities. J Autism Dev Disord 2015; 45(4): 1103–1113.

183 Anderson GM, Stahl SS. Two proposed early biomarker tests of ASD: more harm than good. J Autism Dev Disord 2014; 44(4): 988–989.